Stephen Harrison, MD
Gastroenterology · Live Oak, TXNPI 1104805506
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $708,185 of the $726,972 with a category attached, or 97.4%. 26 manufacturers reported payments, led by Echosens North America, Inc. at 45.6% of the total. Reporting peaked in 2022 at $277,896 and has fallen 86.9% since, to $36,427 in 2024. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $5507.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Echosens North America, Inc.$331K
- Perspectum Diagnostics Ltd$288K
- Merck$20K
- Intercept Pharmaceuticals, Inc.$18K
- Gilead$14K
- AbbVie$10K
- plus $45K from 20 others
Across 367 payments — averaging $13,342 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Genentech, Inc.$880K
- E.r. Squibb & Sons, L.L.C.$836K
- Intercept Pharmaceuticals, Inc.$526K
- Boehringer Ingelheim$516K
- Gilead$270K
- plus $749K from 12 others
What the payments were for
- Consulting fees$708,18597%
- Speaking & faculty fees$9,1101%
- Grants$6,0001%
- Travel & lodging$2,2770%
- Food & beverage$1,4000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Echosens North America, Inc. | 36 | $331,405 |
| Perspectum Diagnostics Ltd | 19 | $288,042 |
| Merck | 3 | $19,870 |
| Intercept Pharmaceuticals, Inc. | 17 | $18,411 |
| Gilead | 15 | $14,326 |
| AbbVie | 3 | $10,029 |
| Boehringer Ingelheim | 4 | $7,019 |
| Corcept Therapeutics | 2 | $6,300 |
| GSK | 4 | $5,911 |
| Theratechnologies Inc. | 2 | $5,900 |
| Genentech, Inc. | 2 | $4,706 |
| Dexcom, Inc. | 3 | $4,560 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,550 |
| Regeneron | 1 | $1,828 |
| AstraZeneca | 3 | $1,697 |
| Pfizer | 1 | $1,260 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $868 |
| ERBE USA Inc | 1 | $81 |
| Novo Nordisk | 2 | $55 |
| La Jolla Pharmaceutical Company | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $31 |
| Olympus America Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FibroScan$331,405
- LiverMultiScan$288,042
- Korlym$6,300
- Mavyret$6,000
- Non-Covered Product$4,706
- MK-3655$1,875
- XIFAXAN$750
How this compares
$726,972 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Live Oak
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.